You've probably heard of BPC-157 for gut healing and KPV for inflammation. LL-37 is the antimicrobial peptide in the same conversation that gets less attention — partly because its name is less memorable, and partly because the conditions it's most relevant to (chronic UTIs, biofilm infections, mucosal immunity) don't generate the same social media engagement as weight loss or skin peptides.
For women dealing with recurrent infections or autoimmune-driven inflammation, LL-37 is worth understanding.
What LL-37 does
LL-37 is a cathelicidin — a class of antimicrobial peptides your body produces naturally as part of the innate immune system. It's expressed in epithelial cells, neutrophils, macrophages, and other immune cells. Its biological functions span three domains:
Direct antimicrobial activity. LL-37 kills bacteria by inserting into and disrupting their cell membranes. This mechanism is fundamentally different from conventional antibiotics (which target specific bacterial processes like cell wall synthesis or protein production). Because LL-37 attacks the membrane structure itself, bacteria have a harder time developing resistance to it — the membrane is too essential to evolve around.
Biofilm disruption. Biofilm is a polysaccharide matrix that bacteria build around themselves as a protective shield. Biofilm-protected bacteria are up to 1,000 times more resistant to antibiotics than free-floating bacteria. Chronic UTIs, chronic sinusitis, and implant-associated infections often involve biofilm. LL-37 can penetrate and disrupt biofilm structure, potentially making the bacteria inside susceptible to antibiotics or immune clearance.
Immune modulation. Beyond killing bacteria directly, LL-37 acts as a chemokine — it recruits immune cells to the site of infection, modulates the inflammatory response, and influences the balance between pro- and anti-inflammatory signaling. This dual role (antimicrobial + immunomodulatory) is what makes LL-37 relevant beyond simple infection control.
Why women specifically
Chronic UTIs. Over 50% of women will experience at least one UTI in their lifetime. Of those, 25-30% will have recurrent infections. Standard treatment — courses of antibiotics — addresses acute infection but often fails to eradicate biofilm in the bladder wall, leading to recurrence. LL-37's biofilm-disrupting capability is mechanistically relevant to breaking the recurrence cycle.
Vaginal microbiome. The vaginal epithelium produces LL-37 as part of its natural defense against pathogenic bacteria and yeast. Women with recurrent bacterial vaginosis (BV) or vulvovaginal candidiasis have been found to have lower mucosal LL-37 levels in some studies, suggesting that LL-37 deficiency may contribute to infection susceptibility.
Autoimmune conditions. 80% of autoimmune patients are women. LL-37's immunomodulatory properties are relevant to conditions where chronic inflammation and aberrant immune signaling drive tissue damage. LL-37 doesn't suppress the immune system — it modulates it, potentially redirecting an overactive immune response toward appropriate targets.
How LL-37 is used
LL-37 is available through compounding pharmacies (by prescription) and research peptide suppliers. Delivery methods include subcutaneous injection (most common for systemic effects), nebulized inhalation (for respiratory applications), and topical application (for wound healing).
For UTI-related use, some functional medicine clinicians prescribe subcutaneous LL-37 as part of a broader protocol that may include BPC-157 (for mucosal repair), biofilm-disrupting supplements (N-acetyl cysteine, lactoferrin), and targeted antibiotics when culture-proven infection is present.
This combined approach reflects the complexity of chronic biofilm infections: no single agent is likely to resolve the problem, and LL-37's value is as one component of a multi-mechanism strategy rather than a standalone cure.
What the honest assessment looks like
LL-37 is a well-characterized molecule with clear biological functions. Its antimicrobial, antibiofilm, and immunomodulatory properties are supported by substantial preclinical research. But "well-characterized mechanism" is not the same as "proven clinical treatment."
For women with chronic UTIs that haven't responded to repeated antibiotic courses, LL-37 represents a mechanistically rational option — not a guaranteed one. For women with autoimmune-driven inflammation, LL-37 is worth discussing with a provider who understands its immunomodulatory profile — alongside, not instead of, established treatments.
If you pursue LL-37, do so through a licensed provider who can supervise the protocol, monitor your response, and integrate it with appropriate conventional care. The peptide is promising. The evidence is early. Both things are true.